OPDUALAG & LOGO (VERSION II)

View On IC.GC.CA

REGISTERED

on 1 Dec 2023

Last Applicant/ Owned by

BRISTOL-MYERS SQUIBB COMPANY

Route 206 & Province Line RoadPrinceton, NJ 08543

Serial Number

2091939 filed on 15^th Mar 2021

Registration Number

TMA1211786 registered on 1^st Dec 2023

Registration expiry Date

1^st Dec 2033

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 16001 FIRST CANADIAN PLACE100 KING STREET WESTTORONTO

ONTARIO

M5X1G5

OPDUALAG & LOGO (VERSION II)

Trademark usage description

pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosi Read More

Vienna Information

26 . 2 . 1

Segments of circles or ellipses (except 26.2.7)Segments de cercle ou d'ellipse (excepté 26.2.7)

26 . 11 . 1

One line or one bandUne ligne ou une bande

26 . 11 . 2

Two lines or bandsDeux lignes ou bandes

26 . 11 . 6

Thick lines, bandsLignes épaisses, bandes

26 . 11 . 11

Broken lines or bands (except a 26.11.13)Lignes ou bandes brisées (excepté a 26.11.13)

26 . 11 . 12

Curved lines or bands (except a 26.11.13)Lignes ou bandes courbes (excepté a 26.11.13)

27 . 5 . 1

Letters presenting a special form of writingLettres présentant un graphisme spécial

27 . 5 . 7

Letters surmounted by a sign of disproportionate size -- Note: Includes, for instance, a letter i surmounted by a disproportionate dot, by a star or a flower.Lettres surmontées d'un signe de dimension disproportionnée -- Note: Comprend par exemple la lettre i surmontée d'un point disproportionné, d'une étoile ou d'une fleur.

27 . 5 . 11

Letters underlined, overlined, framed or barred by one or more strokesLettres soulignées, surlignées, encadrées ou barrées d'un ou de plusieurs traits

Classification Information

Class [005]
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disorders, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical and biological preparations for human use, namely, immunotherapies; pharmaceutical preparations for human use, namely, T-cells for medical purposes; pharmaceutical preparations for human use, namely, cells for medical purposes for the treatment of cancer and auto-immune diseases; diagnostic pharmaceutical preparations for human use, namely, diagnostic kits consisting primarily of cells for medical laboratory use; pharmaceutical preparations for human use, namely, kits comprised of cells and pharmaceuticals for medical laboratory use for the treatment of cancer and auto immune diseases;

Classification kind code

Class [044]
Health care services, namely, providing information to physicians, health care professionals and patients on the topic of health issues, health awareness and pharmaceuticals; Providing information in the field of healthcare and pharmaceutical preparations via a website.

Classification kind code

Mark Details

Serial Number

2091939

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 135 on 6^th Sept 2023	Amendment to Application
Submitted for opposition 27 on 17^th Aug 2023	Approval Notice Sent
Submitted for opposition 26 on 17^th Aug 2023	Approved
Submitted for opposition 15 on 3^rd Aug 2023	Correspondence Created
Submitted for opposition 22 on 4^th Apr 2023	Search Recorded
Submitted for opposition 20 on 4^th Apr 2023	Examiner's First Report
Submitted for opposition 287 on 29^th Jun 2022	Pre-Assessment Letter Sent
Submitted for opposition 30 on 15^th Mar 2021	Filed
Submitted for opposition 1 on 15^th Mar 2021	Created
Submitted for opposition 31 on 15^th Mar 2021	Formalized

OPDUALAG & LOGO (VERSION II)

Classification Information

Classification kind code

Class [044]Health care services, namely, providing information to physicians, health care professionals and patients on the topic of health issues, health awareness and pharmaceuticals; Providing information in the field of healthcare and pharmaceutical preparations via a website.

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [044]
Health care services, namely, providing information to physicians, health care professionals and patients on the topic of health issues, health awareness and pharmaceuticals; Providing information in the field of healthcare and pharmaceutical preparations via a website.